Brain as an HIV sequestered site

Use of nanoparticles as a therapeutic option

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalProgress in Brain Research
Volume180
Issue numberC
DOIs
StatePublished - 2009

Fingerprint

Nanoparticles
Blood-Brain Barrier
HIV
Brain
Therapeutics
Viral Load
Pharmaceutical Preparations
Central Nervous System
Inflammation

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Brain as an HIV sequestered site : Use of nanoparticles as a therapeutic option. / Destache, Christopher J.

In: Progress in Brain Research, Vol. 180, No. C, 2009, p. 225-233.

Research output: Contribution to journalArticle

@article{c9ad03faa5804578aa314f611127ae81,
title = "Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option",
abstract = "Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.",
author = "Destache, {Christopher J.}",
year = "2009",
doi = "10.1016/S0079-6123(08)80012-X",
language = "English",
volume = "180",
pages = "225--233",
journal = "Progress in Brain Research",
issn = "0079-6123",
publisher = "Elsevier",
number = "C",

}

TY - JOUR

T1 - Brain as an HIV sequestered site

T2 - Use of nanoparticles as a therapeutic option

AU - Destache, Christopher J.

PY - 2009

Y1 - 2009

N2 - Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.

AB - Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.

UR - http://www.scopus.com/inward/record.url?scp=77953416319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953416319&partnerID=8YFLogxK

U2 - 10.1016/S0079-6123(08)80012-X

DO - 10.1016/S0079-6123(08)80012-X

M3 - Article

VL - 180

SP - 225

EP - 233

JO - Progress in Brain Research

JF - Progress in Brain Research

SN - 0079-6123

IS - C

ER -